Photochemotherapy for localized morphoea: effect on clinical and molecular markers

Usmani, N.; Murphy, Anthony B.; Veale, Douglas J.; Goulden, V.; Goodfield, M. J. D.

doi:10.1111/j.1365-2230.2008.02890.x

Cited by 32 publications

(29 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thirty patients with morphea have been prospectively treated with PUVA. 26,47 Eighty percent of them reportedly showed improvement via skin score with or without ultrasound measurement. 26,47 Seventy-five patients with morphea have been prospectively treated with broadband UVA.…”

Section: Ultrasoundmentioning

confidence: 99%

See 1 more Smart Citation

Update on morphea

Fett¹,

Werth²

2011

Journal of the American Academy of Dermatology

161

View full text Add to dashboard Cite

Morphea is a rare fibrosing disorder of the skin and underlying tissues. The underlying pathogenesis of morphea is not completely understood at this time, but ultimately results in an imbalance of collagen production and destruction. Evidence-based treatment options of morphea are limited secondary to the rarity of the disease, and the lack of universally used validated outcome measures. The most commonly used outcome measures are skin scores, computerized surface area measurement, durometer, cutometer, thermography, and ultrasound measurements. The Localized Scleroderma Cutaneous Assessment Tool is a promising recently validated skin scoring tool that allows differentiation between activity and damage, is sensitive to change, and requires no additional equipment. The most robust data in the treatment of morphea exists for methotrexate in combination with systemic steroids and ultraviolet A1.

show abstract

Section: Ultrasoundmentioning

confidence: 99%

“…26,47 Eighty percent of them reportedly showed improvement via skin score with or without ultrasound measurement. 26,47 Seventy-five patients with morphea have been prospectively treated with broadband UVA. 48,49 Approximately 77% of these patients were reported to have ''fair'' or better clinical response to therapy.…”

Section: Ultrasoundmentioning

confidence: 99%

Update on morphea

Fett¹,

Werth²

2011

Journal of the American Academy of Dermatology

161

View full text Add to dashboard Cite

show abstract

“…Ancak PUVA'nın lokalize sklerodermadaki etkinliği ile ilgili veriler, genellikle retrospektif özellikte, sınırlı sayıda hastayı içeren çalışmalardan doğmaktadır. On üç hastayı içeren, açık, prospektif bir çalışmada, haftada iki PUVA uygulaması ile, ortanca 28 seans sonunda, deri skorlarında ortalama %62,9'luk bir azalma elde edilmiştir (78). Yirmi sekiz hastanın banyo PUVA ile tedavi edildiği bir çalışmada, hastaların %39'unda ortalama 71 seans sonunda tam yanıt, %50'sinde ise ortalama 51 seans sonunda kısmi yanıt ortaya çıkmıştır (79).…”

Section: Sklerozan Hastalıklarda Fototerapiunclassified

Current Approach to Phototherapy Applications in Dermatology Practice: Part 2. Phototherapy in Vitiligo, Mycosis Fungoides, Atopic Dermatitis, Sclerosing Diseases and Psoriasis

Gençosmanoğlu¹

2017

tdd

View full text Add to dashboard Cite

“…Alternativ kann die UVB-311-nmPhototherapie eingesetzt werden. Zwar ist die Bade-PUVA-Therapie insbesondere für die akut entzündliche Phase der LS geeignet ( [19,20,21], . Abb.…”

Section: Therapieunclassified

Lokalisierte Sklerodermie (Morphea) im Kindesalter

Weibel

2012

Hautarzt

View full text Add to dashboard Cite

Localized scleroderma or morphea is a sclerosing connective tissue disease of the skin, which may affect underlying tissues such as subcutis, muscle and bone. Many patients show extracutaneous symptoms and antinuclear antibodies, however, secondary transformation into systemic sclerosis does not occur. Localized scleroderma usually begins in childhood with a wide variation in its clinical spectrum. The linear variant is the most common subtype in children, associated with a progressive course and increased risk of complications. The disease may progress over years and result in severe functional and cosmetic disability. The etiology of localized scleroderma remains unknown. A genetic background is suspected, while triggers such as trauma, vaccinations and infections may lead to secondary immunologic phenomena. Localized scleroderma often remains unrecognized for a long time, resulting in substantial delay in treatment. The combination of systemic corticosteroids and methotrexate has been established as first-line therapy for progressive (usually linear) disease, whereas phototherapy (UVA-1 or UVB-narrow band) is suitable for adolescents with superficial circumscribed subtypes.

show abstract

Photochemotherapy for localized morphoea: effect on clinical and molecular markers

Cited by 32 publications

References 25 publications

Update on morphea

Update on morphea

Current Approach to Phototherapy Applications in Dermatology Practice: Part 2. Phototherapy in Vitiligo, Mycosis Fungoides, Atopic Dermatitis, Sclerosing Diseases and Psoriasis

Lokalisierte Sklerodermie (Morphea) im Kindesalter

Contact Info

Product

Resources

About